)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Marksans Pharma
Marksans Pharma (MARKSANS) investor relations material
Marksans Pharma Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary13 Aug, 2026
Executive summary
Q1 FY27 revenue rose 35.6% YoY to ₹840.8 crore; record EBITDA of ₹213 crore and PAT of ₹159.4 crore, with quarter-end cash of ₹1,058 crore.
UK & Europe revenue surged 74.7% YoY to ₹356 crore, including ₹44 crore from QliniQ; acquisitions and broad-based growth strengthened the European platform.
Management maintained FY27 guidance and plans to pursue geographic expansion, product launches and selective acquisitions.
Financial highlights
Operating revenue was ₹840.8 crore versus ₹620 crore in Q1 FY26, up 35.6% YoY; underlying growth excluding QliniQ was 28.5%.
Gross profit increased 38.9% YoY to ₹497.3 crore; gross margin expanded 138 bps to 59.1%.
EBITDA more than doubled to ₹213 crore; margin rose 919 bps YoY to 25.3%.
PAT rose 173.9% YoY to ₹159.4 crore; net profit margin was 18.4%.
Operating cash flow was ₹185 crore; after ₹33 crore net CapEx, free cash flow was ₹152 crore.
Outlook and guidance
FY27 revenue growth guidance of 15%-20% and EBITDA margin guidance of 20%-21% maintained; management said 21%-22% margin is achievable.
Revenue expected to improve in Q2 versus Q1, with Q3 potentially strongest; management expects to meet its margin plan.
Management reiterated a ₹4,000 crore revenue target within two years and a goal to double revenue within five years.
Europe is expected to generate EUR 180 million; QliniQ is expected to contribute ₹150-175 crore revenue in FY27.
Longer-term ambitions include ₹1,000 crore revenue in Europe within five years and U.S. benchmarks of $300 million near term and $400 million longer term.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Marksans Pharma
- Sales and profit surged as merger-led expansion advanced alongside cost and regulatory risks.MARKSANS
Q4 04/05 - Sales rose 18.47% as expansion advanced across APIs and global markets.MARKSANSQ4 05/06
- API price erosion cut earnings as investment continued in capacity and regulated-market growth.MARKSANSQ4 06/07
- FY08 PBT more than doubled as overseas expansion advanced, amid input-cost risks.MARKSANSQ4 07/08
- Q4 standalone profit rebounded, while consolidated losses and FX exposure persisted.MARKSANSQ4 09/10
- Revenue growth and FCCB settlements restored profitability, with market and execution risks still material.MARKSANSQ4 12/13
- FCCB default and API-sale charges overwhelmed improving formulation operations.MARKSANSQ4 10/11
- Impairments and overdue FCCBs overshadowed rising exports and improved consolidated revenue.MARKSANSQ4 11/12
- FY14 delivered 43.7% revenue growth, 56.7% PAT growth and a 19.13% EBITDA margin.MARKSANSQ4 13/14
- FY15 growth accelerated as QIP funding and Time Cap Labs backed US expansion.MARKSANSQ4 14/15
Next Marksans Pharma earnings date
Q2 26/275 Nov, 2026
Marksans Pharma
Next Marksans Pharma earnings date
Q2 26/275 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Marksans Pharma Limited is a pharmaceutical company engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company produces a wide range of dosage forms including tablets, capsules, liquids, and ointments across therapeutic areas such as pain management, gastrointestinal, cardiovascular, and anti-infective segments. It serves regulated and semi-regulated markets including the United States, Europe, Australia, and emerging regions. Marksans Pharma Limited operates manufacturing facilities compliant with global regulatory standards and offers contract manufacturing services. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.